Zydus Lifesciences vs Dr. Reddy’s: share price, P/E, ROE and financials compared
Zydus Lifesciences
Dr. Reddy's Laboratories
Zydus Lifesciences and Dr. Reddy’s at a glance
Zydus Lifesciences and Dr. Reddy’s are both listed in Healthcare. Zydus Lifesciences is the larger by market cap, at ₹1.2L Cr against ₹1.1L Cr for Dr. Reddy’s. On valuation, Zydus Lifesciences has the lower P/E (28.6× against 40.9×), while Dr. Reddy’s has the lower price-to-book (2.96× against 4.29×). On returns and margins, Zydus Lifesciences has the higher ROCE (19.0% against 14.2%), the higher ROE (14.7% against 7.3%) and the higher operating margin (26.2% against 15.9%). Over three years, Zydus Lifesciences has faster 3-year sales growth (+16.5% against +11.0% a year) and faster 3-year profit growth (+37.0% against −1.7% a year). Dr. Reddy’s carries less debt for its equity, with a debt-to-equity of 0.19× against 0.46×.
Key metrics, side by side
| Metric | Zydus LifesciencesZYDUSLIFE | Dr. Reddy’sDRREDDY |
|---|---|---|
| Price (₹) | 1,197.90 | 1,373.00 |
| Market cap (₹ Cr) | 1,19,491 | 1,14,462 |
| P/E | 28.6× (the lower figure, shaded) | 40.9× |
| P/B | 4.29× | 2.96× (the lower figure, shaded) |
| Dividend yield, trailing | 0.08% | 0.58% (the higher figure, shaded) |
| ROE | 14.7% (the higher figure, shaded) | 7.3% |
| ROCE | 19.0% (the higher figure, shaded) | 14.2% |
| Operating margin (OPM) | 26.2% (the higher figure, shaded) | 15.9% |
| Net margin (NPM) | 13.8% (the higher figure, shaded) | 8.5% |
| Sales CAGR 3Y | +16.5% (the higher figure, shaded) | +11.0% |
| Profit CAGR 3Y | +37.0% (the higher figure, shaded) | −1.7% |
| Debt to equity | 0.46× | 0.19× (the lower figure, shaded) |
| Interest cover | 19.1× (the higher figure, shaded) | 15.7× |
| Net profit TTM (₹ Cr) | – | 2,799 |
| 1Y return | +22.8% (the higher figure, shaded) | +13.8% |
| Promoter holding | – | 26.63% |
Zydus Lifesciences vs Dr. Reddy’s: common questions
Which is bigger, Zydus Lifesciences or Dr. Reddy’s?
By market cap, Zydus Lifesciences is bigger at ₹1.2L Cr, against ₹1.1L Cr for Dr. Reddy’s (prices as of 6 Nov 2026).
Which has a lower P/E ratio, Zydus Lifesciences or Dr. Reddy’s?
Zydus Lifesciences trades at a P/E of 28.6× and Dr. Reddy’s at 40.9×. Zydus Lifesciences has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Zydus Lifesciences or Dr. Reddy’s?
Zydus Lifesciences reports a return on equity of 14.7% and Dr. Reddy’s 7.3%. Zydus Lifesciences has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Zydus Lifesciences or Dr. Reddy’s?
Over the last three years: Sales grew +16.5% a year at Zydus Lifesciences and +11.0% at Dr. Reddy’s, so Zydus Lifesciences grew sales faster; profit grew +37.0% a year at Zydus Lifesciences and −1.7% at Dr. Reddy’s, so Zydus Lifesciences grew profit faster. Past growth doesn’t predict future growth.